SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.13-0.6%Jan 13 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Home-Run who wrote (2031)5/5/1998 6:45:00 AM
From: Z Analyzer  Read Replies (3) of 9523
 
Here's a shocker! For those wondering why PFE hasn't gone up further despite great prescription numbers, this could explain it. The Viagra related increase in fizer's share price should be the sum of discounted future cash flows.
ASSUMPTIONS 1)Viagra sales of $2 bil in 1998, $4 bil in 1999, $6 bil in 2000 to 2009 expiration. 2) EPS increase of $.25 per share per billion.
CONCLUSIONS Viagra will bring in REVENUES of just $63 billion (Pfizer's market cap increased by more than $63 bil in just over a year). Viagra's EPS totals just $15.75 per share over its LIFETIME. Applying a 15% discount rate to the earnings stream, produces a present value of $6.37 per share which is the amount investors should be willing to pay for Viagra's earnings stream in addition to Phizer's base business valuation (look at share price before Viagra runup or assume 30 p/e on $2.00 EPS for $60 base).
I personally believe that EPS should increase by more than the $.25 per share per billion but even a max of $.40 doesn't alter the conclusion which is that the stock already reflects the hype and irrational valuations unless you believe my revenue figures are GROSSLY understated.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext